***KAST*** SILVER SPRINGS, NV / ACCESSWIRE / December 15, 2016 / Kasten, Inc. (KAST) announced today it has signed a term sheet to joint venture with Pettersson Adams Medical Research.
Pettersson is engaged in developing innovative health products utilizing unique and patented technologies. They have developed a technology designed to treat and reverse the plaques that accumulate in the brain thus enhancing the quality of life, the cognitive functions of the brain and improving overall brain health. The technology is centered and targeted on the delivery of compounds both transdermal and transintestinal. The technology developed by Pettersson not only treats the symptoms but also addresses the environment in the body that causes the symptoms.
Plaques in the brain can not only lead to brain abnormality but death. Intracranial stenosis is a narrowing of an artery inside the brain. A buildup of plaque (atherosclerosis) inside the artery wall reduces blood flow to the brain. Atherosclerosis that is severe enough to cause symptoms carries a high risk of stroke and can lead to brain damage and death. In addition, one of the hallmarks of Alzheimer's disease is the accumulation of amyloid plaques between nerve cells (neurons) in the brain. The technology developed by Pettersson to treat and reverse plaques that accumulate in the brain has the potential to save millions of lives and provide hope to those that are suffering with Alzheimer's disease and dementia.
Both parties have 45 days to conduct and complete due diligence. Upon successful due diligence testing, Kasten believes it can create and maintain a successful marketing program to introduce the technology to the marketplace. The companies are also exploring a distribution agreement.
Kasten, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of medical therapies designed to prevent and/or treat serious medical conditions. Kasten is principally focused on delivering solutions to those medical conditions for which the care pathway is burdened by high morbidity, mortality, and cost.
CONTACT:
Kasten, Inc.
702-860-2407
pr@kastenbiopharma.com
SOURCE: Kasten, Inc.
